- Home
- SCWO vs IPHA Comparison
SCWO vs IPHA Comparison
Compare SCWO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- IPHA
- Stock Information
- Founded
- SCWO 2021
- IPHA 1999
- Country
- SCWO United States
- IPHA France
- Employees
- SCWO 26
- IPHA N/A
- Industry
- SCWO Environmental Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SCWO Utilities
- IPHA Health Care
- Exchange
- SCWO Nasdaq
- IPHA Nasdaq
- Market Cap
- SCWO 64.3M
- IPHA 150.9M
- IPO Year
- SCWO N/A
- IPHA 2019
- Fundamental
- Price
- SCWO $0.45
- IPHA $1.95
- Analyst Decision
- SCWO
- IPHA Strong Buy
- Analyst Count
- SCWO 0
- IPHA 1
- Target Price
- SCWO N/A
- IPHA $11.50
- AVG Volume (30 Days)
- SCWO 405.6K
- IPHA 50.9K
- Earning Date
- SCWO 03-28-2025
- IPHA 03-20-2025
- Dividend Yield
- SCWO N/A
- IPHA N/A
- EPS Growth
- SCWO N/A
- IPHA N/A
- EPS
- SCWO N/A
- IPHA N/A
- Revenue
- SCWO $313,930.00
- IPHA $36,202,722.00
- Revenue This Year
- SCWO N/A
- IPHA N/A
- Revenue Next Year
- SCWO $5,180.00
- IPHA $101.65
- P/E Ratio
- SCWO N/A
- IPHA N/A
- Revenue Growth
- SCWO N/A
- IPHA N/A
- 52 Week Low
- SCWO $0.44
- IPHA $1.29
- 52 Week High
- SCWO $1.99
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SCWO 28.52
- IPHA 56.50
- Support Level
- SCWO $0.54
- IPHA $1.72
- Resistance Level
- SCWO $0.58
- IPHA $1.92
- Average True Range (ATR)
- SCWO 0.05
- IPHA 0.11
- MACD
- SCWO 0.00
- IPHA 0.02
- Stochastic Oscillator
- SCWO 11.06
- IPHA 89.74
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The business activities of the company include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.